CUSIP No. 925050106
Schedule 13G
Item 1.
Verona Pharma plc (the “Issuer”).
| (b) | Address of Issuer’s Principal Executive Offices: |
3 More London Riverside
London SE1 2RE
United Kingdom
Item 2.
| (a) | Name of Person Filing: |
This filing is being made on behalf of (collectively, the “Access Filers”):
AI Biotechnology LLC
Access Industries Holdings LLC
Access Industries Management, LLC
Len Blavatnik
| (b) | Address of Principal Business Office or, if none, Residence: |
The principal business office of each reporting person is c/o Access Industries, Inc., 40 West 57th Street, 28th Floor, New York, NY 10019.
Each of AI Biotechnology LLC, Access Industries Holdings LLC and Access Industries Management, LLC is a limited liability company organized under the laws of the State of Delaware.
Mr. Blavatnik is a citizen of the United States of America.
| (d) | Title of Class of Securities: |
Ordinary shares, nominal value £0.05 per share (“Ordinary Shares”).
925050106
Item 3. | If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a: |
| | | | |
| | |
(a) | | ☐ | | Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o); |
| | |
(b) | | ☐ | | Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c); |
| | |
(c) | | ☐ | | Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c); |
| | |
(d) | | ☐ | | Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8); |
| | |
(e) | | ☐ | | An investment adviser in accordance with §240.13d-1(b) (1)(ii)(E); |
| | |
(f) | | ☐ | | An employee benefit plan or endowment fund in accordance with §240.13d-1(b) (1)(ii)(F); |
6